Argenx Se ARGX
NASDAQ ARGX
$1,036.49 -16.97 (-1.61%)
As of: Sep 4, 2026 · 12:49 PM EDT

Argenx Se (ARGX) Net Income (2016 - 2026)

Argenx Se's (ARGX) quarterly Net Income came in at $482.0 million in Q2 2026, up 248.37% YoY from $138.4 million in Q2 2025, and up 27.51% on a QoQ basis from $378.0 million in Q1 2026.

Analysis

Argenx Se (ARGX) Net Income (2016 - 2026) Analysis & Trends

Argenx Se (ARGX) has 11 years of Net Income data on file, last reported at $482.0 million in Q2 2026.

  • Quarterly Net Income rose 248.37% year-over-year to $482.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.8 billion (up 51.26% YoY) and the FY2025 annual result came in at $1.3 billion, down 17.42% from the prior year.
  • Net Income rose to $482.0 million in Q2 2026, from $378.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $771.5 million in Q4 2024 to a low of -$241.3 million in Q1 2022.
  • A 5-year average of $111.0 million and a median of $97500.0 in 2023 frame the typical range for Net Income.
  • Annual changes were most pronounced in 2022 — Net Income slumped 1435.49% — and 2024, when it jumped 877.94%.
  • Tracing ARGX's Net Income over 5 years: stood at -$38.6 million in 2022, then plunged by 156.84% to -$99.2 million in 2023, then jumped by 877.94% to $771.5 million in 2024, then slumped by 30.92% to $532.9 million in 2025, then decreased by 9.56% to $482.0 million in 2026.
  • The last three Net Income figures came in at $482.0 million (Q2 2026), $378.0 million (Q1 2026), and $532.9 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn 601.00 Mn
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.05 Bn 44.05 Bn - -644.37 Mn
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.52 Bn 27.68 Bn - 81.49 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -13.27 Mn
10 Incyte 25.59 Bn 21.05 Bn 1.57 Bn 585.61 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 601.00 Mn
Mar 31, 2026 499.00 Mn
Dec 31, 2025 273.64 Mn
Sep 30, 2025 427.85 Mn
Jun 30, 2025 328.44 Mn
Mar 31, 2025 235.36 Mn
Dec 31, 2024 -603.80 Mn
Sep 30, 2024 84.64 Mn
Jun 30, 2024 -59.07 Mn
Mar 31, 2024 -87.10 Mn
Dec 31, 2023 -23.18 Mn
Sep 30, 2023 -93.92 Mn
Jun 30, 2023 -73.35 Mn
Mar 31, 2023 -123.49 Mn
Dec 31, 2022 -43.86 Mn
Sep 30, 2022 -247.01 Mn
Jun 30, 2022 -225.21 Mn
Mar 31, 2022 -232.96 Mn
Dec 31, 2021 -251.94 Mn
Sep 30, 2021 -228.12 Mn